Condition: Pseudomyxoma Peritonei · Sponsor: Oslo University Hospital
Participants will receive vaccination with Pseudovax/GM-CSF in combination with PD-1 inhibitor tislelizumab over a period of up to two years. The vaccine is expected to reactivate measurable immune response, and tislelizumab to restore anticancer immunity in patients with GNAS mutated pseudomyxoma peritonei.
This description comes directly from the study's public registry record.
Geir Olav Hjortland, Medical Doctor - Oncologist · +47 22934000 · kreftstudier@ous-hf.no
Always discuss trial participation with your own doctor first.
| Oslo University Hospital HF, Radium | Oslo, Oslo, Norway | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07341360